Please login to the form below

Not currently logged in
Email:
Password:

Movetis launches Resolor in Germany

First market introduction of Movetis' lead medicine for chronic constipation

Following the approval of Resolor (prucalopride) in the European Economic Area in October 2009, Movetis has launched the prescription only drug in Germany. It will be used for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief.

Prucalopride is the first molecule from the Movetis portfolio that has been developed into a marketed medicinal product. Movetis is a spinoff of Johnson & Johnson, established in Belgium in 2006, to develop innovative drugs for the treatment of diseases in the gastrointestinal (GI) area.

Resolor is a once-a-day oral product, available in 1mg and 2mg tablets and meets the criteria for reimbursement in Germany. 

Dirk Reyn, chief executive officer of Movetis, said: "The launch of Resolor in Germany is yet another important milestone in the relatively short history of Movetis. The market introduction in Germany was scheduled for the first quarter of 2010, and we have clearly achieved this objective. Every day we receive more and more questions from physicians, illustrating there is a clear interest for a product such as Resolor."

Movetis plans to launch Resolor in the UK in the second quarter of 2010.

The company has a broad portfolio of GI products in development for conditions including ascites, paediatric reflux, refractory gastroesophageal reflux disease and severe forms of irritable bowel syndrome.

27th January 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...

Infographics